These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 34944858)

  • 1. Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment.
    Tymon-Rosario J; Adjei NN; Roque DM; Santin AD
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
    Yardley DA
    Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
    Rivera E; Lee J; Davies A
    Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
    Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel cytotoxic agents: epothilones.
    Goodin S
    Am J Health Syst Pharm; 2008 May; 65(10 Suppl 3):S10-5. PubMed ID: 18463327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epothilones in the treatment of ovarian cancer.
    Diaz-Padilla I; Oza AM
    Future Oncol; 2011 Apr; 7(4):559-68. PubMed ID: 21463144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.
    Rosenberg JE; Galsky MD; Rohs NC; Weinberg VK; Oh WK; Kelly WK; Small EJ
    Cancer; 2006 Jan; 106(1):58-62. PubMed ID: 16329138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review.
    Zagouri F; Sergentanis TN; Chrysikos D; Dimopoulos MA; Bamias A
    Onco Targets Ther; 2015; 8():2187-98. PubMed ID: 26316786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
    Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
    Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer.
    Ho J; Zhang L; Todorova L; Whillans F; Corey-Lisle P; Yuan Y
    J Manag Care Pharm; 2009; 15(6):467-75. PubMed ID: 19610679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer.
    Bhushan S; Walko CM
    Ann Pharmacother; 2008 Sep; 42(9):1252-61. PubMed ID: 18648018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer.
    Vishnu P; Colon-Otero G; Kennedy GT; Marlow LA; Kennedy WP; Wu KJ; Santoso JT; Copland JA
    Gynecol Oncol; 2012 Mar; 124(3):589-97. PubMed ID: 22115851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer.
    Goodin S
    Am J Health Syst Pharm; 2008 Nov; 65(21):2017-26. PubMed ID: 18945860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with epothilones in patients with breast cancer.
    Buzdar AU
    Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.
    De Geest K; Blessing JA; Morris RT; Yamada SD; Monk BJ; Zweizig SL; Matei D; Muller CY; Richards WE
    J Clin Oncol; 2010 Jan; 28(1):149-53. PubMed ID: 19917861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones.
    Pronzato P
    Drugs; 2008; 68(2):139-46. PubMed ID: 18197722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile and potential of ixabepilone in the treatment of pancreatic cancer.
    Smaglo BG; Pishvaian MJ
    Drug Des Devel Ther; 2014; 8():923-30. PubMed ID: 25075175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
    Vahdat L
    Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
    Boehnke Michaud L
    J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.
    Dumontet C; Jordan MA; Lee FF
    Mol Cancer Ther; 2009 Jan; 8(1):17-25. PubMed ID: 19139109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.